Algorae Pharmaceuticals's book value per share for the quarter that ended in Dec. 2025 was A$0.00.
During the past 3 years, the average Book Value Per Share Growth Rate was -30.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -21.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -22.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Algorae Pharmaceuticals was 32.60% per year. The lowest was -45.00% per year. And the median was -16.15% per year.
During the past 13 years, the highest P/B Ratio of Algorae Pharmaceuticals was 21.45. The lowest was 0.45. And the median was 1.27.
Warning Sign:
Algorae Pharmaceuticals Ltd stock PB Ratio (=13.5) is close to 5-year high of 13.5.
Algorae Pharmaceuticals (ASX:1AI) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Algorae Pharmaceuticals Book Value per Share Related Terms
Algorae Pharmaceuticals Book Value per Share Historical Data
* Premium members only.
The historical data trend for Algorae Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Algorae Pharmaceuticals Book Value per Share Chart
ASX:1AI vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Algorae Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Algorae Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Algorae Pharmaceuticals's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Algorae Pharmaceuticals (ASX:1AI) has a Book Value per Share of A$0.00 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Algorae Pharmaceuticals and its competitors.
Is Algorae Pharmaceuticals' Book Value per Share too high?
Algorae Pharmaceuticals' current Book Value per Share is A$0.00.
How does Algorae Pharmaceuticals' Book Value per Share compare to VRTX and REGN?
Algorae Pharmaceuticals' Book Value per Share of A$0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Algorae Pharmaceuticals and its competitors. Algorae Pharmaceuticals's current Book Value per Share is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Algorae Pharmaceuticals stock overvalued right now?
Algorae Pharmaceuticals (ASX:1AI) has a current Book Value per Share of A$0.00. The current Book Value per Share is A$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Algorae Pharmaceuticals (ASX:1AI), the current Book Value per Share is A$0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:1AI has been successfully added to your 